Immunome IMNM Business Segments — Indirect Research And Development Expense

Similar metrics at other companies

ALMSSingle Reportable — Research And Development Expense

$81.54M-15.6%

ALMSSingle Reportable — Research And Development Facilities And Overhead Costs

$5.37M+3.5%

AVBPSingle Reportable — Research And Development Expense Personnel Related And Other Internal Costs

$10.23M+70.3%

ALMSSingle Reportable — Other Research And Development Expense

$2.37M+3.2%

CLDXSingle Reportable — Research And Development Expense

$73M+38.7%

CAPRSingle Reportable — Research And Development Expense

$27.38M+44.7%

Questions, answered.

What is Immunome's business segments — indirect research and development expense?

Immunome (IMNM) reported business segments — indirect research and development expense of -$16.31M in Q1 2026.

How has Immunome's business segments — indirect research and development expense changed year-over-year?

Immunome's business segments — indirect research and development expense decreased by 57.8% year-over-year, from -$10.34M to -$16.31M.

What is the long-term trend for Immunome's business segments — indirect research and development expense?

Over 2 years (2023 to 2025), Immunome's business segments — indirect research and development expense has grown at a 111.1% compound annual growth rate (CAGR), from $11.81M to $52.62M.

What does business segments — indirect research and development expense mean?

Represents the overhead and support costs necessary to maintain the research and development infrastructure, such as facility costs, administrative support for labs, and general R&D management. These expenses are not directly tied to a specific clinical or preclinical program but are essential for the overall R&D function. It serves as a measure of the fixed cost burden required to operate the company's research engine.